Trial · NCT04818086
Outcomes31
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 31
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Pulse Oximetry During the Baseline Visit | Baseline visit (Safety measure) | Baseline | percentage of oxygen saturation | MEAN |
| PRIMARY | Change in Pulse Oximetry During Week 1 Visit | Week 1 visit, safety measure | Week 1 | percentage of oxygen saturation | MEAN |
| PRIMARY | Change in Pulse Oximetry During Week 2 Visit | Week 2 visit, safety measure | Week 2 | percentage of oxygen saturation | MEAN |
| PRIMARY | Change in Blood Pressure During Baseline Study Visit | Baseline Visit, safety measure | Baseline | mmHg (millimeters of mercury) | MEAN |
| PRIMARY | Change in Blood Pressure During Week 1 Study Visit | Week 1 visit, safety measure | Week 1 | mmHg (millimeters of mercury) | MEAN |
| PRIMARY | Change in Blood Pressure During Week 2 Study Visit | Week 2 visit, safety measure | Week 2 | mmHg (millimeters of mercury) | MEAN |
| PRIMARY | Change in Patient Consciousness During the Baseline Visit | Baseline visit, safety measure | Baseline | score on a scale | MEAN |
| PRIMARY | Change in Patient Consciousness During the Week 1 Study Visit | Week 1 visit, safety measure | week 1 | score on a scale | MEAN |
| PRIMARY | Change in Patient Consciousness | Week 2 visit, safety measure | week 2 | score on a scale | MEAN |
| PRIMARY | Change in Buprenorphine Plasma Concentration (PK) During the Baseline Visit | Baseline visit | Baseline | Nanograms/milliliter (ng/mL) | MEAN |
| PRIMARY | Change in Buprenorphine Plasma Concentration (PK) During Week 1 Study Visit | Week 1 | Week 1 | Nanograms/milliliter (ng/mL) | MEAN |
| PRIMARY | Change in Buprenorphine Plasma Concentration (PK) During Week 2 Study Visit | Week 2 | Week 2 | Nanograms/milliliter (ng/mL) | MEAN |
| PRIMARY | Change in Lemborexant PK During Baseline Study Visit | Baseline visit | Lemborexant serum levels are not provided as the detailed methods for lemborexant level determination are proprietary and we do not have access to those methods. Hence, we are not able to provide the lemborexant levels. Currently, we have no pathway to obtain the lorcaserin PK results. The reason for that is the methods used for the original lorcaserin human PK testing are proprietary and we would have to re-do all of that research ourselves, which is outside the scope of what we are able to do. | ||
| PRIMARY | Change in Lemborexant PK During Week 1 Study Visit | Week 1 visit | Lemborexant serum levels are not provided as the detailed methods for lemborexant level determination are proprietary and we do not have access to those methods. Hence, we are not able to provide the lemborexant levels. Currently, we have no pathway to obtain the lorcaserin PK results. The reason for that is the methods used for the original lorcaserin human PK testing are proprietary and we would have to re-do all of that research ourselves, which is outside the scope of what we are able to do. | ||
| PRIMARY | Change in Lemborexant PK During Week 2 Study Visit | Week 2 visit | Lemborexant serum levels are not provided as the detailed methods for lemborexant level determination are proprietary and we do not have access to those methods. Hence, we are not able to provide the lemborexant levels. Currently, we have no pathway to obtain the lorcaserin PK results. The reason for that is the methods used for the original lorcaserin human PK testing are proprietary and we would have to re-do all of that research ourselves, which is outside the scope of what we are able to do. | ||
| PRIMARY | Change in Respiration During the Baseline Study Visit (Pre- to Post-dose) | Baseline visit | Baseline | mmHg (millimeters of mercury) | MEAN |
| PRIMARY | Change in Respiration During the Week 1 Study Visit (Pre- to Post-dose) | Week 1 visit | Week 1 | millimeters of mercury (mmHg) | MEAN |
| PRIMARY | Change in Respiration During Week 2 Study Visit (From Pre- to Post-dose) | Week 2 visit | Week 2 | mmHg (millimeters of mercury) | MEAN |
| SECONDARY | Change in Drug Effects During Baseline Study Visit (Pre- to Post- Dose) | Baseline visit | Baseline | score on a scale | MEAN |
| SECONDARY | Change in Drug Effects During Week 1 Study Visit (Pre- to Post- Dose) | Week 1 visit | Week 1 | score on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04818086/outcomes